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Abstract
Osteocytes are the most abundant osteoblast lineage cells within the bone matrix. They respond to
mechanical stimulation and can participate in the release of regulatory proteins that can modulate
the activity of other bone cells. We hypothesize that neuropeptide Y (NPY), a neurotransmitter with
regulatory functions in bone formation, is produced by osteocytes and can affect osteoblast activity.
To study the expression of NPY by the osteoblast lineage cells, we utilized transgenic mouse models
in which we can identify and isolate populations of osteoblasts and osteocytes. The Col2.3GFP
transgene is active in osteoblasts and osteocytes, while the DMP1 promoter drives green fluorescent
protein (GFP) expression in osteocytes. Real-time PCR analysis of RNA from the isolated
populations of cells derived from neonatal calvaria showed higher NPY mRNA in the preosteocytes/
osteocytes fraction compared to osteoblasts. NPY immunostaining confirmed the strong expression
of NPY in osteocytes (DMP1GFP+), and lower levels in osteoblasts. In addition, the presence of
NPY receptor Y1 mRNA was detected in cavaria and long bone, as well as in primary calvarial
osteoblast cultures, whereas Y2 mRNA was restricted to the brain. Furthermore, NPY expression
was reduced by 30–40% in primary calvarial cultures when subjected to fluid shear stress. In addition,
treatment of mouse calvarial osteoblasts with exogenous NPY showed a reduction in the levels of
intracellular cAMP and markers of osteoblast differentiation (osteocalcin, BSP, and DMP1). These
results highlight the potential regulation of osteoblast lineage differentiation by local NPY signaling.
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Neuropeptide Y (NPY) is a 36-amino acid polypeptide that belongs to the larger family of
neuropeptides, which also includes the pancreatic polypeptide and the peptide YY [Tatemoto
et al., 1982; Allen et al., 1992]. NPY signals through a class of receptors known as Y receptors,
members of the G-protein-coupled receptors [Lemos et al., 1997; Raimondi et al., 2002]. The
Y receptor system consists of five Y receptors; Y1, Y2, Y4, Y5, and Y6 (which is present only
in the mouse). NPY is highly expressed in the hypothalamus, and its receptors Y1, Y2, and Y5
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are found in the central nervous system, including the hypothalamus [Sar et al., 1990; Parker
and Herzog, 1999].
Functionally, NPY is a potent orexigenic peptide; its expression is up-regulated in the
hypothalamus of experimental diabetic rats [Sahu et al., 1990; la Fleur et al., 2003]. NPY acts
through the Y2 receptor in the hypothalamus to centrally regulate bone mass [Baldock et al.,
2002]. This observation was reinforced using germline deletion of Y2 or Y1 receptors in mice,
resulting in a higher trabecular bone volume and elevated cortical bone mass [Baldock et al.,
2005]. Moreover, targeted deletion of Y2 in the hypothalamus revealed an increased bone
volume comparable to the effect of germ line deletion of Y1 or Y2 in mice, thus confirming
the Y2-mediated central regulation of bone mass [Baldock et al., 2005]. In contrast to the
germline Y1 deletion, Y1-targeted deletion in the hypothalamus did not affect the bone mass
in mice indicating the possibility for a local NPY-Y1 signaling pathway in the bone tissue,
especially since mouse stromal cells expresses Y1 [Baldock et al., 2007]. Thus, central NPY,
acting through Y2 receptors, is known to affect bone mass. However, within the bone
microenvironment, it is still unclear whether the actions of Y1 receptors result from local
production of NPY, and if so, what cell type(s) are responsible. In adipose tissue, local
production of NPY by adipocytes has been shown to regulate fat mass [Kuo et al., 2007]. Thus,
we examined the production of NPY within the osteoblast lineage, and the effect of this
production on cell function.
Studying the gene expression profile of the bone cells in mice has become easier due to the
availability of transgenic mice in which promoters of bone-specific genes direct the green
fluorescent protein (GFP) expression. For instance, transgenic mice in which GFP is under the
control of either the 3.6 kb or the 2.3 kb of the rat col1a1 promoter fragment has enabled the
isolation of relatively homogenous populations of preosteoblasts and mature osteoblasts,
respectively [Kalajzic et al., 2002]. In the case of the osteocyte, it has been shown that dentin
matrix protein 1 (DMP1) is preferentially expressed in cells embedded within the bone matrix
(osteocytes) or in partially embedded cells (preosteocytes). This was the key observation
leading to the generation of an osteocyte-specific GFP transgenic mouse (DMP1GFP) that can
be used to selectively isolate this terminally differentiated population of osteoblast lineage cells
[Kalajzic et al., 2004].
An intriguing observation was the expression of NPY in the Col2.3GFP population of mature
osteoblasts with an increase in expression in DMP1GFP-positive population. In this study, we
evaluated the expression of NPY in osteoblast lineage cells and studied the effects of NPY on
osteoprogenitor lineage differentiation. This study defines NPY as a local regulator of
osteoblast lineage activity that shows a response in relation to in vitro mechanical stimulation.
Materials and Methods
TRANSGENIC MICE MODELS
3 kb col1a1 GFP—To define cells as mature osteoblasts we utilized a transgenic mouse in
which a 2.3-kb fragment of collagen type I promoter directs the expression of emerald or cyan
variants of GFP to mature osteoblasts lineage cells (Col2.3GFPemd or Col2.3CFPc-yan)
[Kalajzic et al., 2002].
DMP1 promoter-directed GFP expression—To define cells as osteocytes we used a
previously developed transgenic mouse in which a DMP1 regulatory sequence directs the
expression of the GFP transgene primarily to osteocytes (DMP1GFPtpz) [Kalajzic et al.,
2004].
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Transgenic lines were crossed to generate dual GFP-expressing Col2.3GFPcyan/
DMP1GFPtopaz mice that were used for histological analysis and isolation of osteoblast and
osteocytes by flow cytometry. All procedures involving the use of animals were approved by
University of Connecticut Health Center Institutional Animal Care Committee (protocol #
ACC 2007-344).
Separation of cell populations—Calvaria were isolated from 5-to 8-day-old double
transgenic mice (pOBCol2.3-GFPcyan and DMP1GFPtopaz) sacrificed by CO2 asphyxiation.
After the removal of the sutures, calvarial tissues were subjected to four sequential, 30-min
long digestions in a mixture containing 0.05%/0.2 mM trypsin/EDTA and 1.5 U/ml
collagenase-P (Roche) at 37°C. Cell fractions 2–4 were collected, pooled, and resuspended in
Dulbecco's modified Eagle's medium (DMEM; Life Technologies) containing 10% fetal calf
serum (FBS). Cells were resuspended in PBS, filtered through a 70-μm cell strainer,
centrifuged, resuspended in the PBS/2% FBS. Cell sorting was performed using a FACS-
Vantage BD cell sorter with a 130-μm nozzle at a speed of 3–5K cells/s. Sorting was performed
using appropriate lasers to distinguish GFPcyan+ from GFPtopaz+ expressing cells. Sorting
allowed us to separate DMP1GFPtpz+ osteocytes from Col2.3GFPcyan+ osteoblasts.
Calvarial Osteoblast Culture
Calvarial cells were isolated from 7-day-old neonatal mice using a modified protocol developed
by Wong and Cohn [Wong and Cohn, 1975; Kalajzic et al., 2002]. Calvaria were subjected to
four sequential 30-min digestions in an enzyme mixture containing 0.05% trypsin and 1.5 U/
ml collagenase P at 37°C. Cell fractions 2–4 were pooled and enzyme activity was terminated
by the addition of media containing FBS. Cells were plated at a density of 1.5 × 105 cells/well
in 6-well culture dishes in DMEM with 10% FBS and switched to differentiation medium
(αMEM containing 10% FBS, 50 μg/ml ascorbic acid, 4mM β-glycerophosphate) when they
reached confluence.
Preparation Of Cryosections
Bone tissues were fixed for 3–4 days in 4% paraformaldehyde/PBS (pH 7.4) at 4°C, decalcified
for 3 days, placed in 30% sucrose/PBS overnight, and embedded (Cryomatrix, Thermo
Shandon, Pittsburgh). Bones were cryosectioned at 5 μm sections using a CryoJane tape
transfer system (Instrumedics, NJ). After rehydration in 1 mM MgCl2/physiological saline,
GFP expression was observed and photographed (Zeiss Axiovert 200 M microscope and
Axiocam digital camera; Zeiss) using GFP-variant specific filters (Chroma; Rockingham, VT)
[Kalajzic et al., 2008]. A dual bandpass design was used to distinguish GFP signal from
autofluorescence of bone and bone marrow.
Immunostaining
For immunofluorescent labeling primary calvaria cells were prepared as indicated above.
Following activation of the DMP1GFP transgene, cells were sorted into DMP1GFP+ and
DMPGFP1− populations. Briefly, cells were enzymatically digested using 0.2% collagenase/
0.2% hyalouronidase in 2.5% trypsin at 37°C. Cells were collected and resuspended in DMEM
(Life Technologies) containing 10% FBS (Hyclone) and centrifuged. Cells were resuspended
in PBS, filtered through a 70-μm cell strainer, centrifuged, resuspended in the PBS/2% FBS,
and filtered through a 45-μm filter. Cell sorting was performed using a FACS-Vantage BD cell
sorter with a 130-μm nozzle at a speed of 3–5K cells/s. Sorting was performed using an argon
laser to excite GFPtopaz-expressing cells at 488 nm employing a 550/30 emission filter.
Following sorting, cells were replated on collagen-coated 2 mm2 cover slide chamber plates
(0.15 mg/ml, rat type I collagen). Cells were fixed for 10 min in 4% PFA, and after washing
in PBS, cells were blocked with 5% normal donkey serum, before incubating with rabbit anti-
Igwe et al. Page 3
J Cell Biochem. Author manuscript; available in PMC 2009 October 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
NPY (1:1,000 dilutions, Cat: ab10980, Abcam, Inc., MA) at 4°C overnight. Signal was detected
with donkey anti-rabbit conjugated with CY3.
Histochemical Analysis Of Cell Cultures
Histochemical staining for ALP activity was performed using a commercially available kit (86-
R ALP; Sigma Diagnostics, Inc., MO) according to the manufacturer's instruction.
Mineralization was assessed using the von Kossa silver nitrate staining method. The results of
staining procedures were recorded using a scanner (UMax Astra 4000U) and Adobe Photoshop.
Rna Extraction And Real-Time Pcr
Total RNA was isolated from tissues or cell cultures using TRIzol reagent (Invitrogen, USA).
RNA samples were subjected to cDNA synthesis, and gene expression analysis was completed
using semiquantitative and real-time PCR. A quantity of 3 μg of total RNA was reverse
transcribed in a 20-μl reaction mixture containing 50 ng random hexamers mix together with
200 U of Superscript III reverse transcriptase according to the manufacturer's instructions for
Superscript III first strand synthesis (Invitrogen). Real-time PCR was carried out using the
TaqMan Gene Expression Assays (Applied Biosystems, CA) (assay ID:Dmp1,
Mm01208365_m1, BSP, Mm00492555_M1). For RT-PCR, we used the following primers:
NPY, forward 5′-GTTTCAGGGGATGAGATGAG-3′, reverse 5′-
GCTCTGCGACACTACATCAA-3′; Y1, forward 5′-CTCGCTGGTTCTCATCGCTG
TGGAACGG-3′, reverse 5′-gcgaatgtatatcttgaagtag-3; Y2, forward 5′-
TCCTGGATTCCTCATCTGAG-3′, reverse 5′-ggtccagagcaatgactgtc-3′, 18s forward 5′-
tcaagaacg aaagtcggagg-3′, reverse 5′-ggacatctc cgggccacaca-3′ [Lundberg et al., 2007].
Northern Blot Analysis
Total RNA (10μg) was separated on a 2.2 M formaldehyde/1% agarose gel and transferred
onto a nylon membrane (Maximum Strength Nytran Plus, Schleicher & Schuell). Membranes
were probed with the 900 bp PstI fragment of rat Col1a1 (pα1R2) [Genovese et al., 1984], and
a 440-bp mouse OC fragment (p923) [Celeste et al., 1986]. Probes were radiolabeled by the
random primer method using (α-32P) dCTP (New England Nuclear, 3,000 Ci/mmol) to obtain
probes with specific activities of approximately 1 × 109 cpm/μg. Filters were hybridized with
3 × 106 cpm/ml 32P-labeled probe at 42°C in 50% formamide, 5× SSPE (1× SSPE = 0.149 M
NaCl, 10 mM NaH2PO4, 1mM EDTA, pH 7.4), 1.2× Denhardt's, and 0.5% sodium dodecyl
sulfate and washed according to published procedures.
In Vitro Shear Stress
Fluid shear stress (FSS) was performed using the previously described fluid flow chamber
[Wadhwa et al., 2002]. The fluid flow system includes a flow chamber, a roller pump
(Masterflex, IL), a tubing, and a water bath kept at 37°C. The fluid flow generates a uniform
flow field in which the magnitude and direction of the velocity vector are constant with flow
rate of 280 ml/min, generating FSS of 10 dynes/cm2, applied at a frequency of 5 Hz. Mouse
calvarial osteoblasts were isolated by sequential digestion as described above. Cells were
cultured for 7 days in DMEM supplemented with 10% FBS, 1% penicillin/streptomycin, and
1% nonessential amino acid, and then re-plated on slides coated with type I collagen (rat tail
collagen, Collaborative Biomedical Products, Bedford, MA, 50 μg/ml) at a density of 100,000
cells/slide and cultured in a 4-well slide chamber plate. Twenty-four hours after re-plating,
cells were switched to osteogenic media (see the Calvarial Osteoblast Culture Section) and
cultured for 10 days additional until cells started to form mineralized nodules. The media were
changed to low concentration FBS (1%) 1 h before subjecting cells to FSS for 30 min in the
same media. After exposure to FSS, cells (including the controls) were cultured in the same
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media for 30 min before RNA was extracted from the cultures and prepared as described above
for real-time PCR.
Intracellular Cyclic Amp Measurement
Following NPY treatment, cells were scraped into 500 μl of ice-cold ethanol. The ethanolic
cell suspension was collected in tubes and centrifuged at 1,500g for 10 min at 4°C. Supernatants
were collected and lyophilized. The dried residue was dissolved in EIA buffer and cAMP was
measured according to the manufacturer's instructions (Cayman Chemicals, Ann Arbor, MI).
The cAMP activity was normalized to the total protein in the sample measured by BCA protein
assay (Pierce, USA).
Statistical Analysis
To compare differences in mean, we used unpaired t-test. ELISA data were normalized to
protein concentration. P < 0.05 was considered statistically significant.
Results
Detection Of Npy Expression In Cells Of Osteoblasts Lineage
To investigate NPY expression in cells of the osteoblast lineage, we analyzed the RNA derived
from different tissues of 2-month-old mice. NPY mRNA was detected in mouse calvaria,
femur, and in the brain, which was used as a positive control (Fig. 1A). Lower expression of
NPY was observed in heart, kidney, and adipose tissue. To further evaluate the expression of
NPY during the different stages of osteoblast lineage differentiation, we utilized previously
developed transgenic mice in which promoter-GFP transgenes were directed to specific stages
of lineage differentiation. We generated primary neonatal calvarial cultures and separated cells
based on GFP expression using flow cytometry cell sorting. We focused the analysis on sorted
GFP+ and GFP− cells derived from Col2.3GFP and DMP1-GFP transgenic mice, as they direct
GFP in areas of mineralization (Fig. 1B). RT-PCR analysis of RNA from the sorted cells shows
strong NPY mRNA expression in the Col2.3GFP+ and DMP1-GFP+ cells (Fig. 1C). Since the
Col2.3GFP-positive cells also contain the osteocyte population, we aimed to identify if the
NPY expression is localized in the mature osteoblasts or within the preosteocyte/osteocyte
population. In order to evaluate this, we utilized dual color transgenic mice obtained by
breeding of Col2.3GFPcyan and DMP1-GFPtopaz mice to isolate mature osteoblasts
(Col2.3GFPcyan+, DMP1GFPtpz−) and osteocytes (DMP1GFPtpz+). Col2.3GFP cyan is
expressed in osteoblast lining bone surfaces and in some osteocytes, while DMP1GFP is active
in osteocytes and preosteocytes (cells that are fully or partially embedded within the matrix)
(Fig. 2A). Real-time PCR analysis of RNA from these fractions demonstrated that NPY
expression is significantly higher in the preosteocyte/osteocyte fraction than in osteoblasts (Fig.
2B,D). Similar results on NPY gene expression in sorted cells were obtained by comprehensive
microarray analysis of RNA derived from sorted osteoblasts and osteocytes (data not shown).
Detection Of Npy Protein In Cells Of Osteoblast Lineage
Having determined that NPY mRNA is expressed in cells of the osteoblast lineage, we
investigated whether NPY protein could be detected in primary bone cell cultures of transgenic
mice. Cells derived from DMP1-GFP mice were cultured for 7 days in basal media and then
placed under osteogenic induction for another 10 days. We observed that DMP1-GFP was
expressed in association with mineralized nodules (Fig. 3A,B). Cultures were enzymatically
digested and cells were sorted into DMP1-GFP+ (Fig. 3C) and DMP1-GFP− (Fig. 3D). DMP1-
GFP+ and DMP1-GFP− cells were immunostained for NPY expression. Consistent with the
mRNA results, NPY immunoreactivity was observed in DMP1-GFP+ cells (Fig. 3E), while
weaker but detectable NPY expression was observed in DMP1-GFP− cells (Fig. 3F).
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Expression Of Npy Receptors In Osteoblasts
The Y1 and Y2 receptors are known to play a major role in NPY-dependent central regulation
of bone formation. Therefore, we evaluated their expression in various tissues including
calvaria and long bones. RNA analysis demonstrated the presence of Y1 mRNA in the calvarial
and long bone tissues as well as in the other organs including heart, kidney, muscle, and adipose
tissue (Fig. 4A). Y2 expression was observed in the brain, but was not detected in the calvaria
or long bones (Fig. 4A), or in cultured mouse calvarial osteoblasts (data not shown). We
evaluated the expression of NPY Y1 in mouse primary calvarial osteoblasts. Quantitative real-
time PCR of RNA from cultured calvarial osteoblasts revealed an increase of NPY Y1
expression as the osteoprogenitors differentiate and mineralize in culture (Fig. 4B). The
expression of alkaline phosphatase is observed by day 7 and increases at later time points (Fig.
4C). More mature stages of osteoblast lineage are detected by expression of bone sialoprotein
(BSP) and DMP1 at days 14 and 21 along with mineralization (Fig. 4C–E).
Fluid Shear Stress Negatively Regulates Npy Expression In The Osteoblast Lineage Cells
We have previously shown that DMP1 expression is responsive to in vivo and in vitro
mechanical stimulation [Yang et al., 2005]. Here we evaluated whether the expression of NPY
by the osteoblast lineage cells is regulated by in vitro FSS using DMP-1 as the positive readout
for FSS. Following 3 weeks in culture, calvarial osteoblasts grown on rat type 1 collagen-coated
slides were fully differentiated to a stage containing mineralizing nodules. The mineralized
cultures were subjected to FSS for 30min at 10 dynes/cm2. After 30 min of post-shear stress
culture, the RNA levels of DMP1 and NPY were assessed. As determined by quantitative real-
time PCR, NPY mRNA levels were significantly decreased by 35% (P<0.05, n = 3) (Fig. 5A),
while the mRNA level of DMP1 was increased twofold (Fig. 5B). These results suggest that
NPY expression is negatively regulated by FSS.
Role Of Npy On In Vitro Osteoblastogenesis
The observation that the expression of NPY-Y1 receptor in the osteoblast increases with time
in culture (Fig. 4B,C) prompted us to evaluate whether NPY has the ability to regulate
osteoblastic differentiation. In order to test this, we cultured mouse calvarial osteoblasts in the
presence of 1 nM NPY for 20 days and then monitored the expression of markers of osteoblast
differentiation. Primary calvarial osteoblasts cultured in the presence of NPY exhibited no
detectable difference in the expression of ALP at days 7 and 14. However, decreased mineral
deposition as detected by von Kossa staining (Fig. 6A) was observed by day 21 of culture. In
addition, RNA analysis of NPY-treated cells demonstrated decreased expression of BSP,
osteocalcin (OC) and DMP1 at days 14 and 21 of culture (Fig. 6B–D).
Npy Treatment Decreased Intracellular Camp In Mouse Calvarial Osteoblasts
NPY-Y1 is classified as a G-protein-coupled receptor that can inhibit adenylate cyclase activity
[Amano et al., 2007]. We aimed to evaluate whether the NPY treatment can modulate the levels
of intracellular cAMP and explain the decrease in osteoblast differentiation markers observed
in our NPY-treated osteoblasts. After treating calvarial osteoblasts with 10nM NPY for 1 h,
we observed a 30% decrease in cAMP (data not shown). Because of the low level of cAMP in
unstimulated osteoblasts, we validated this observation by evaluating the effect of NPY on
forskolin-induced release of cAMP in calvarial osteoblast cultures. Treatment of calvarial
osteoblasts with forskolin induced the release of intracellular cAMP at days 7 and 14 of culture
(Fig. 7B,C). Consistent with the observation in Figure 7A, NPY significantly blunted forskolin-
induced cAMP levels (Fig. 7B–D). In addition, this effect of NPY was mediated mostly via
NPY-Y1 signaling since NPY-Y1 receptor blocker BIB03304 blunted this effect (Fig. 7D).
These results indicate that NPY/NPY-1 signaling can alter the intracellular cAMP levels in
osteoblast cells and modulate osteogenic differentiation.
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Discussion
Over the last two decades, since the discovery of NPY, its expression has been thought be
exclusive to the brain [Tatemoto, 1982]. However, NPY expression has been observed in other
tissues. For instance, the white adipocytes were reported to synthesize and release NPY (Fig.
1A) [Kuo et al., 2007; Yang et al., 2008]. In this study, we present evidence for the first time
of the expression of the NPY by the cells of the osteoblast lineage. Bone tissue is well innervated
and it had been previously reported that NPY immunoreactivity was associated with the nerve
endings along vascular elements within the bone [Hill and Elde, 1991]. Here, using DMP1-
GFP, Col2.3-GFP, and DMP1-GFP/Col2.3-GFP dual transgenic mice, we were able to isolate
population of cells that are highly enriched with mature osteoblasts (Col2.3-GFP) and
osteocytes (DMP1-GFP and DMP1-GFP/Col2.3-GFP). This enabled us to perform gene
expression analysis on RNA from these two different cell populations. We detected greater
NPY mRNA expression in the fractions that were highly enriched with mature osteoblasts and
osteocytes. Osteocytes are characterized by a specific morphology that distinguishes them from
other bone cells; they also share some of these features with the neuronal cells, such as extensive
network of processes that run through out the bone tissue. Much like the neuronal processes,
osteocytes processes may actively participate in the release of regulatory proteins that can
modulate the activity of other bone cells. One of such proteins is NPY, a neurotransmitter with
functions in energy and bone regulation. The possibility of NPY expression by the bone cells
is not surprising as other cells within the bone marrow niche such as the megakaryocytes and
the leukocytes has been shown to express NPY [Holler et al., 2008].
Local production of NPY in the bone could indicate a novel alternative pathway to the
previously described hypothalamic-mediated central regulation of bone, which requires Y2
expression on the pre-synaptic nerve ending to maintain the feedback inhibition of NPY release
[King et al., 2000; Sainsbury et al., 2002]. This is plausible since we did not detect Y2 in any
of the bone cells including the osteocytes and therefore a non-Y2-regulated source of NPY
may represent a potential alternate peripheral source of NPY in the bone tissue. NPY-Y2
signaling is supposedly a part of the hypothalamo-pitutary-corticotropic axis, which is also
involved in the regulation of NPY. The complexity of NPY regulation has been examined at
different levels. Mice lacking either Y2 or leptin receptor demonstrated increased hypothalamic
NPY levels [Wilding et al., 1993; Sainsbury et al., 2002]. In addition, stress and insulin have
also been implicated in the regulation of NPY in the brain [Wilding et al., 1993; Zhou et al.,
2008]. We investigated whether mechanical stimulation regulates NPY expression, since
osteocytes are known to respond to mechanical stress [Aarden et al., 1994; Weinbaum et al.,
1994]. DMP1 expression can be utilized as a marker for studying the response of osteocytes
to mechanical loading [Yang et al., 2005; Harris et al., 2007]. The DMP1 protein is found
within the lacunae and along the processes of mature osteocytes, where it is believed to
contribute to the mechanosensory properties of the osteocytes. In a model of shears stressed
cells, DMP1 response was observed after 30 min. In contrast to the increase in DMP1 mRNA,
the expression of NPY was decreased in an in vitro shear stress model. Taken together, our
observation demonstrates that the expression of NPY in the bone cells is responsive to
mechanical stress. This shows some similarity to the regulation of NPY by different stressor
elements in the brain [Thorsell et al., 1998]. The potential mechanism and the signaling
cascades within the osteoblast lineage require further studies.
NPY signaling is known to occur via the Y receptors, with the Y1 and Y2 being implicated in
the regulation of bone formation. In this study, we evaluated whether NPY acting through its
Y1 receptor could influence osteoblastic differentiation. Our findings indicate that osteoblasts
cultured in the presence of NPY exhibited decreased expression of markers of differentiation,
OC, bone sailoprotein, and DMP1 and a decrease in the extent of mineralization. This finding
mirrors an earlier observation in which osteoblast cultures from mice lacking Y1 exhibited
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increased differentiation potential and high bone mass, while in another study NPY infusion
in mice resulted in decreased osteoid width [Baldock et al., 2007; Allison et al., 2008]. Taken
together these observations suggest a potential role for the local NPY-Y1 signaling in osteoblast
biology.
The NPY-Y1 receptors are G-protein-coupled receptors and have been shown to inhibit the
activity of adenylate cyclase and consequently decreases the cAMP levels, we therefore
hypothesized that the mechanism underlying NPY regulation of osteoblast maturation lies in
its ability to decrease the intracellular cAMP levels in these cells [Amano et al., 2007]. To test
this hypothesis, we cultured mouse calvarial osteoblasts with or without forskolin in the
presence of NPY or NPY-Y1 receptor inhibitor BIB03304. NPY significantly reduced
forskolin-induced cAMP in cultured osteoblasts. The inhibitory effect of NPY on cAMP levels
in cultured bone cells appears to be mediated through the Y1 receptors, although this does not
exclude the possibility of other undiscovered pathways.
To summarize our study define that NPY is expressed by osteoblast lineage cells and underlines
the potential for a local signaling pathway that can regulate the osteoblast lineage activity.
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Fig. 1.
Detection of NPY mRNA in osteoblast lineage cells. A: Expression of NPY mRNA by RT-
PCR was completed in selected tissues isolated from 2-month-old mice. NPY mRNA was
detected in mouse calvaria, brain, and femur. B: GFP expression in mouse calvarial osteoblasts
cultures. Cells were derived from neonatal GFP calvarial from pOBCol2.3GFP and DMP-1-
GFP (areas undergoing mineralization are indicated by the arrows). The upper panel shows
phase-contrast images, while epifluorescence images are shown in the lower panel. C:
Expression of NPY in pOBCol2.3GFP+ and DMP-1-GFP+ sorted cells. No expression of NPY
was detected in GFP− cells (images were taken at a magnification of 10× (B)).
Igwe et al. Page 11
J Cell Biochem. Author manuscript; available in PMC 2009 October 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2.
Detection of NPY in DMP1GFPtpz/pOBCol2.3GFPcyan dual transgenic mice. A: Expression
of DMP1GFPtpz and pOBCol2.3GFPcyan in calvaria derived from dual GFP transgenic mice.
DMP-1GFPtpz is detected in the cells within calvarial bone, while pOBCol2.3GFPcyan is
detected in cells lining bone surfaces of the parietal bone. B: Real-time PCR analysis of RNA
from freshly isolated calvarial cells obtained from dual transgenic mice (DMP1GFP/
Col2.3GFP). Higher expression of NPY and DMP-1 was observed in DMP1GFPtopaz+
population than in Col2.3GFPcyan+ cells. A representative experiment out of three different
biological experiments is presented (images were taken at a magnification of 20× (A)).
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Fig. 3.
Detection of NPY protein by immunofluorescence. A,B: DMP1-GFP expression in mouse
calvarial osteoblast cell cultures at day 16 prior to cell sorting under epifluorescence (A) and
phase contrast (B). C: Epifluorescent image of DMP1+ cells after sorting. D: Epifluorescent
imaging shows no GFP expression in DMP1− cells following sorting. E: DMP1+ cells and (F)
DMP1− cells immunostained for NPY (red, TRITC+), and nuclear staining (blue, DAPI). A
strong immunoreactivity was observed in DMP1+ cells (E), while a lower but detectable
expression was observed in DMP1− cells (F).
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Fig. 4.
Detection of NPY-Y1 receptors. A: In vivo detection of NPY-Y1 and Y2 by RT-PCR in
selected tissues derived from 2-month-old mice. B: mRNA expression of NPY-Y1 by real-
time PCR in samples of cultured mouse calvarial osteoblasts. RNA was isolated on days 7, 14,
and 20; values represent mean ± SE (n = 3) from a representative experiment. C: Alkaline
phosphatase expression (days 7–20) and mineralization on days 14 and 20 by Von Kossa (black
spots) indicate differentiation of the osteoprogenitor cells. D,E: Real-time PCR analysis for
BSP and DMP1 gene expression. Data shown are obtained from one of the three representative
experiments and are expressed as the relative gene expression ratio to day 7. Both BSP and
DMP1 expression are very low or undetectable on day 7. Following osteogenic induction, an
increase in both BSP and DMP1 is observed by days 14 and 21.
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Fig. 5.
Regulation of NPY expression by FSS. A,B: The effect of in vitro fluid shear stress on the
expression of NPY in primary mouse calvarial osteoblasts cultures. Fully differentiated mouse
calvarial osteoblast were subjected to shear stress for 30min and then cultured without stress
for 30min. A: Real-time PCR analysis of NPY and (B) DMP1 mRNA levels in loaded and
control samples (values are mean ± SE of three experiments, *P-value = 0.03).
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Fig. 6.
Effect of exogenous NPY on osteoblast cultures. Mouse calvarial osteoblasts were plated at a
density of 1.5 × 105 cells/well in 6-well plates. NPY protein (1 nM) was added in culture media
on day 2 and every second day when media were changed. Cells were switched to
differentiation media on day 7. A: Alkaline phosphatase activity and von Kossa assay showing
no major changes in the expression of ALP, while decreased mineral deposition (dark staining)
in NPY-treated cultures for days 14 and 21 was observed. B,C: Real-time PCR showing mRNA
levels of BSP and DMP1 expression on days 14 and 21, respectively. Values represent mean
± SE of three experiments. D: Northern blot analysis for osteocalcin and type I collagen mRNA
expression.
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Fig. 7.
Effect of NPY on intracellular cAMP levels. A: Effect of treatment with NPY on the
intracellular cAMP levels in primary mouse calvarial osteoblasts cultures. Cells were treated
with 10nM NPY for 1 h while the control group received vehicle only. Values represent cAMP
levels at days 7 and 14, as assessed by ELISA (n = 2). B,C: Effect of NPY on forskolin-induced
intracellular cAMP levels primary calvarial osteoblasts cultures. D: The effect of NPY-Y1
blocker BIB03304 on the regulation of intracellular cAMP levels in primary calvarial
osteoblast cultures. Cells were cultured for 7 days and then treated with forskolin alone or with
either NPY or NPY-Y1 blocker BIB03304 (values are mean ± SD from three experiments).
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